Evidence map›Paper›PMID 41711747›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Discovery of novel coumarin-containing triazolo[1,5-a]pyrimidine derivatives as potent ABCB1 inhibitor for modulation of multidrug resistance.

Nan Ye Hmone, Xuefei Tian, Dandan Zhou, Zhiyi Min, Yingxue Zhao, Shuai Wang, Fen-Er Chen, Ziyu Wang, Xuyao Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nan Ye HmoneSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai, China.
Xuefei TianSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai, China.
Dandan ZhouDepartment of Oncology, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.
Zhiyi MinSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai, China.
Yingxue ZhaoUniversity of International Relations, Beijing, China.
Shuai WangEngineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai, China.
Fen-Er ChenEngineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai, China.
Ziyu WangDepartment of Pharmacy, Huadong Hospital, Fudan University, Shanghai, China.
Xuyao ZhangSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ABCB1-mediated drug efflux is a key determinant of multidrug resistance (MDR) in cancer. To overcome this mechanism, a series of thiol-substituted aminocoumarin-derived, coumarin-containing triazolo[1,5-a]pyrimidine derivatives (5a-5s) was synthesised, and compound 5r (NYH-707) was identified as the most potent ABCB1 inhibitor. NYH-707 markedly restored paclitaxel sensitivity in SW620/Ad300 MDR cells, reducing the IC

Indexed as

Antineoplastic AgentsCoumarinsDrug DiscoveryDrug Resistance, MultipleDrug Resistance, NeoplasmPyrimidinesTriazolesAnimalsATP Binding Cassette Transporter, Subfamily BCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceMolecular Docking SimulationMolecular StructureABCB1 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BcoumarinCoumarinsPyrimidinesTriazolestriazolo(1,5-a)pyrimidineABCB1ABCB1 inhibitorsaminocoumarin-derived coumarinMultidrug resistancetriazolo[1,5-a]pyrimidine

Identifiers

PMID41711747
PMCPMC12922422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.